Progression of bone metastases in patients with prostate cancer -automated detection of new lesions and calculation of bone scan index

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-6

  Kaboteh, Reza ^a   Gjertsson, Peter ^a   Leek, Håkan ^b   Lomsky, Milan ^a   Ohlsson, Mattias ^b,c   Sjöstrand, Karl ^c   Edenbrandt, Lars ^a,b,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c EXINI Diagnostics AB   (Sweden)

Author keywords

Automated detection; Bone metastases; Computer assisted diagnosis; Image analysis; Prostate cancer; Radionuclide imaging

Indexed keywords

DOCETAXEL; MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; AUTOMATION; BONE METASTASIS; BONE SCAN INDEX; BONE SCINTISCANNING; CANCER GROWTH; CANCER PROGNOSIS; COLLIMATOR; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FOLLOW UP; HUMAN; IMAGING SOFTWARE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SWEDEN;

EID: 84887289342     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-64     Document Type: Article

References (16)

1. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
2. Tannock IF, de-Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
4. de-Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
5. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
6. De-Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
7. Scher HI, Beer TM, Higano CS, Anand A, Taplin M-E, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
8. Soloway MS, Hardeman SW, Hickey D, Todd B, Soloway S, Raymond J, Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988, 61:195-202.
9. Noguchi M, Kikuchi H, Ishibashi M, Noda S: Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 2003, 88:195-201.
10. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
11. Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ: Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 2012, 30:519-524.
12. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson P-A, Björk T, Gerdtsson A, Bjartell A: A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol 2012, 62:78-84.
13. Snyder W: Report of the Task Group on Reference Man: A Report/ Prepared by a Task Group of Committee 2 of the International Commission on Radiological Protection. Oxford: Pergamon; 1975.
14. Sadik M, Suurkula M, Höglund P, Järund A, Edenbrandt L: Quality of planar whole-body bone scan interpretations-a nationwide survey. Eur J Nucl Med Mol Imaging 2008, 35:1464-1472.
15. Ore L, Hardoff R, Gips S, Tamir A, Epstein L: Observer variation in the interpretation of bone scintigraphy. J Clin Epidemiol 1996, 49:67-71.
16. Sadik M, Hamadeh I, Nordblom P, Suurkula M, Höglund P, Ohlsson M, Edenbrandt L: Computer-assisted interpretation of planar whole-body bone scans. J Nucl Med 2008, 49:1958-1965.